Aizhan Tastanova
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Aizhan Tastanova has a total of 146 co-authors. Here are the top co-authors by number of shared publications:
- Mitchell Paul Levesque
Department of Dermatology, University of Zurich, University Hospital Zurich, Zurich, Switzerland
142 shared publications - Patrick Turko
Department of Dermatology, University of Zurich, University Hospital Zurich, Zurich, Switzerland
138 shared publications - Phil Fang Cheng
Department of Dermatology, University of Zurich Hospital and Faculty of Medicine, University of Zurich, Zurich, Switzerland
137 shared publications - Reinhard Dummer
Department of Dermatology, University Hospital Zürich, University of Zurich, 8091 Zurich, Switzerland
137 shared publications - Zsolt Balazs
Department of Quantitative Biomedicine, University of Zurich, Zurich, Switzerland
136 shared publications - Andreas Dzung
Department of Dermatology University Hospital Zurich, University of Zurich Zurich Switzerland
135 shared publications
Latest Publications
- Open Access
- 29 April 2026
- Published by Springer Nature in Research Square
A comprehensive single cell atlas of healthy ocular tissue and uveal melanoma reveals mutation- and uveal tract-associated cell states
Uveal melanoma is a rare but aggressive intraocular malignancy with limited therapeutic options and a high risk of metastatic relapse. Although its mutational landscape is well defined, how genetic factors, uveal location, and disease progression shape cell states and the tumor ecosystem remains poorly understood. We integrate single-cell RNA sequencing and spatial transcriptomics across a cohort spanning healthy uveal tissue, primary tumors, and metastases. We uncover a continuous shift in melanoma cell states during disease progression, from differentiated, pigmentation-associated programs toward stress- and epithelial-to-mesenchymal transition-associated states. This trajectory is modulated by uveal tract location, with iris tumors exhibiting a more differentiated phenotype and choroidal tumors enriched for stemness-associated features that localize to melanoma-rich regions correlating with genomic instability. In parallel, genetic background defines distinct melanoma cell states and tumor–immune interactions. Together, these findings define clinically relevant cellular states and provide a framework for understanding metastatic progression and therapeutic vulnerability.
- 29 April 2026
- Published by Springer Nature in Research Square
Open AccessA comprehensive single cell atlas of healthy ocular tissue and uveal melanoma reveals mutation- and uveal tract-associated cell states
Uveal melanoma is a rare but aggressive intraocular malignancy with limited therapeutic options and a high risk of metastatic relapse. Although its mutational landscape is well defined, how genetic factors, uveal location, and disease progression shape cell states and the tumor ecosystem remains poorly understood. We integrate single-cell RNA sequencing and spatial transcriptomics across a cohort spanning healthy uveal tissue, primary tumors, and metastases. We uncover a continuous shift in melanoma cell states during disease progression, from differentiated, pigmentation-associated programs toward stress- and epithelial-to-mesenchymal transition-associated states. This trajectory is modulated by uveal tract location, with iris tumors exhibiting a more differentiated phenotype and choroidal tumors enriched for stemness-associated features that localize to melanoma-rich regions correlating with genomic instability. In parallel, genetic background defines distinct melanoma cell states and tumor–immune interactions. Together, these findings define clinically relevant cellular states and provide a framework for understanding metastatic progression and therapeutic vulnerability.
- Open Access
- 24 November 2025
- Published by American Association for Cancer Research (AACR)
Table ST2 from ROS Induction Targets Persister Cancer Cells with Low Metabolic Activity in NRAS-Mutated Melanoma
Table ST2: Summary of the clinical data corresponding to the primary cell cultures used in this publication
- 24 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessTable ST2 from ROS Induction Targets Persister Cancer Cells with Low Metabolic Activity in NRAS-Mutated Melanoma
Table ST2: Summary of the clinical data corresponding to the primary cell cultures used in this publication
- Open Access
- 24 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Data from ROS Induction Targets Persister Cancer Cells with Low Metabolic Activity in NRAS-Mutated Melanoma
Tumor Profiler Consortium author list
- 24 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Data from ROS Induction Targets Persister Cancer Cells with Low Metabolic Activity in NRAS-Mutated Melanoma
Tumor Profiler Consortium author list
- Open Access
- 24 November 2025
- Published by American Association for Cancer Research (AACR)
Table ST6 from ROS Induction Targets Persister Cancer Cells with Low Metabolic Activity in NRAS-Mutated Melanoma
Table ST6: Differential expressed lipids and their FDRs in sensitive vs resistant cells (negative values are upregulated in sensitive cells).
- 24 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessTable ST6 from ROS Induction Targets Persister Cancer Cells with Low Metabolic Activity in NRAS-Mutated Melanoma
Table ST6: Differential expressed lipids and their FDRs in sensitive vs resistant cells (negative values are upregulated in sensitive cells).
- Open Access
- 24 November 2025
- Published by American Association for Cancer Research (AACR)
Suppl. Figure S8 from ROS Induction Targets Persister Cancer Cells with Low Metabolic Activity in NRAS-Mutated Melanoma
- 24 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSuppl. Figure S8 from ROS Induction Targets Persister Cancer Cells with Low Metabolic Activity in NRAS-Mutated Melanoma
- Open Access
- 24 November 2025
- Published by American Association for Cancer Research (AACR)
Suppl Figure S4 from ROS Induction Targets Persister Cancer Cells with Low Metabolic Activity in NRAS-Mutated Melanoma
S4: Neocuproine is a copper-dependent ROS inducer
- 24 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSuppl Figure S4 from ROS Induction Targets Persister Cancer Cells with Low Metabolic Activity in NRAS-Mutated Melanoma
S4: Neocuproine is a copper-dependent ROS inducer
- Open Access
- 24 November 2025
- Published by American Association for Cancer Research (AACR)
Suppl. Figure S1 from ROS Induction Targets Persister Cancer Cells with Low Metabolic Activity in NRAS-Mutated Melanoma
S1: Evaluation of HST screening.
- 24 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSuppl. Figure S1 from ROS Induction Targets Persister Cancer Cells with Low Metabolic Activity in NRAS-Mutated Melanoma
S1: Evaluation of HST screening.
- Open Access
- 24 November 2025
- Published by American Association for Cancer Research (AACR)
Suppl. Figure S15 from ROS Induction Targets Persister Cancer Cells with Low Metabolic Activity in NRAS-Mutated Melanoma
S15: Tumor response curves in mice for ionophoric copper-chelators in combination with binimetinib.
- 24 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSuppl. Figure S15 from ROS Induction Targets Persister Cancer Cells with Low Metabolic Activity in NRAS-Mutated Melanoma
S15: Tumor response curves in mice for ionophoric copper-chelators in combination with binimetinib.
- Open Access
- 24 November 2025
- Published by American Association for Cancer Research (AACR)
Suppl. Figure S3 from ROS Induction Targets Persister Cancer Cells with Low Metabolic Activity in NRAS-Mutated Melanoma
S3: Correlation between MEKi responsiveness and sensitivity to nNeocuproine
- 24 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSuppl. Figure S3 from ROS Induction Targets Persister Cancer Cells with Low Metabolic Activity in NRAS-Mutated Melanoma
S3: Correlation between MEKi responsiveness and sensitivity to nNeocuproine
- Open Access
- 24 November 2025
- Published by American Association for Cancer Research (AACR)
Suppl. Figure S6 from ROS Induction Targets Persister Cancer Cells with Low Metabolic Activity in NRAS-Mutated Melanoma
S6: Correlation analysis between MEKi and ROS.
- 24 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSuppl. Figure S6 from ROS Induction Targets Persister Cancer Cells with Low Metabolic Activity in NRAS-Mutated Melanoma
S6: Correlation analysis between MEKi and ROS.